Skip to content

Social Cognition,Attentional Network and Nicotine Drug Dependency - A Pharmacological Clinical Trail

Social Cognition,Attentional Network and Nicotine Drug Dependency - A Pharmacological Clinical Trail

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00618280
Acronym
NIKOGEN
Enrollment
101
Registered
2008-02-20
Start date
2008-01-31
Completion date
2010-08-31
Last updated
2012-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tobacco Use Disorder, Schizophrenia

Brief summary

In the present study, we investigate healthy subjects and schizophrenic patients who frequently show very low attentional capacity with functional magnetic resonance imaging (fMRI) and electrophysiology (EEG) during attention-requiring tasks to assess the level of attentional network activity.

Detailed description

Nicotine is improving attentional capacity which goes along with an activation of the attentional network in the brain. So far, however, it is unresolved whether nicotine is used for the purpose of self-medication by those nicotine-dependent subjects who suffer from subclinical or clinical attentional deficits which may sustain nicotine addiction. In the present study, we investigate healthy subjects and schizophrenic patients who frequently show very low attentional capacity with functional magnetic resonance imaging (fMRI) and electrophysiology (EEG) during attention-requiring tasks to assess the level of attentional network activity. It is anticipated that low attentional network activity (during baseline condition, after nicotine challenge and after withdrawal) predicts the degree of nicotine dependence including the strength of withdrawal symptoms and relapse rate after smoking cessation. In addition, we expect that functional variations within alpha4beta2 nAch receptor genotype are associated with attentional capacity and -by extension - with nicotine dependence. Additionally Self-medication of attentional deficits and of increased stress vulnerability may contribute to nicotine-dependence both in schizophrenia patients and healthy subjects. However, very little is known about the effect of nicotine on stress in schizophrenia. In particular social stressors are highly relevant in schizophrenia often resulting in social withdrawal. A factor contributing to the stress-eliciting nature of social interaction is the misidentification of social information during communication with others. The present project aims at an investigation of nicotine effects on such social information processing and its neurophysiological correlates and on social stress responses. Using a 2x2-factorial design effects of nicotine vs. placebo are experimentally investigated in smoking schizophrenia patients in comparison to smoking healthy controls each after an overnight smoking deprivation. Nicotine will be administered by nasal spray delivering a systemic does of 2 mg nicotine. Event-related EEG potentials will be recorded during the presentation of pictures of facial affect and neutral control stimuli to assess social information processing and its neurophysiological correlates. In addition a videotaped semi-standardized conversation skills role-play test will be used as a social stress situation to assess self-reported and non-verbal affective responses.

Interventions

0,5 mg nicotine nasal spray or placebo (pepperspray)

Sponsors

German Research Foundation
CollaboratorOTHER
Heinrich-Heine University, Duesseldorf
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* age 18-55 * informed consent * negative drug-screening (cannabis, amphetamine, opiate, cocaine) * no drug abuse in medical history for last 6 month * no participation of subjects in other pharmacological trials within 6 weeks * negative pregnancy test * use of effective contraception within participation of trial * normotonia (heart rate, RR) * nicotine dependence (Fagerström \>4)or not more than 20 cigarettes /lifetime * nicotine (smoker serum \> 2ng/mL) * DSM-IV criteria for schizophrenia * healthy subjects

Exclusion criteria

* known hypersensitivity towards nicotine or any substance of placebo preparation * adenoids * Rhinitis vaso. * hypersensitivity of air passages * cardiovascular diseases (defined) * neurological diseases (defined) * diabetes mellitus * hyperthyreosis * phaeochromocytoma * Clozapine (schizophrenic)

Design outcomes

Primary

MeasureTime frame
Effect of nicotine or placebo in healthy subjects and schizophrenic patients on attentional network activity in brain with functional magnetic resonance imaging and EEGafter last subject out

Secondary

MeasureTime frame
-Effect of nicotine on a4b2 nAch receptor genotype -Gene Expression of a4b2 nAch -effect of 24 h nicotine withdrawal on modulation special hormones -effect of nicotine on neurophysiological correlates of social stressafter last subject out

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026